In the Spotlight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

In the Spotlight

Pharmaceutical Technology
Volume 3, Issue 32

Editors' Picks of Pharmaceutical Science & Technology Innovations

Pharmaceutical manufacturers can gain various benefits from automated equipment. Automated processes generally require minimal human intervention, which means faster completion times and a lower probability of errors. Many automated machines enable companies to incorporate process analytical technology (PAT) principles in their production procedures. Using PAT can improve manufacturing precision and help companies produce consistent high-quality dosage forms. Automation can also simplify production techniques and thus contribute to lean manufacturing and potential cost savings. The three devices in this month's column demonstrate how automation benefits different parts of the pharmaceutical manufacturing process.

Analytical system provides multiuser capability

PANalytical (Almelo, the Netherlands) introduced its fully automated "CubiX Walk-Up" system for X-ray powder diffraction (XRPD) analysis. The system complies with 21 CFR Part 11 regulations and, unlike other systems, allows multiple users to perform analysis. The instrument analyzes samples in a queue and tracks both samples and users.


CubiX Walk-Up XRPD-analysis system (PANalytical)
In addition, the CubiX system creates reports that show instrument settings, how measurements were obtained, and the results of the analyses. Separate reports are generated for individual users and analyses.

Scientists who are inexperienced with XRPD can use the instrument easily because it incorporates preprogrammed settings for measurement and analysis. The system contains setups for various types of analysis and measurement conditions.

A supervisor can set up the CubiX system and grant rights to other users. Users' rights determine which parts of the spectrum they can select for analysis. The system supports most standard operating procedures.

Encapsulator aids dosage design


SCI HGE 1200 encapsulator (Sancilio and Co.)
The "SCI HGE 1200" hard-gelatin encapsulator from Sancilio and Co. (Riviera Beach, FL) allows users to fill capsules with tablets, powders, granules, or a combination of these materials. Fred Sancilio, the company's CEO, says the unit can fit three different tablets in a capsule. The encapsulator thus allows pharmaceutical companies to create "highly complex combinations of incompatible active ingredients ... in one dosage form," Sancilio remarks. He adds that the machine facilitates mixtures that have sophisticated release profiles.

The encapsulator's design gives it a footprint of 32 in.2 The machine's electronics unit is housed in a waterproof box that hangs on a bar outside the main body. The reduced footprint allows the machine to "fit in places that others can't go," according to Sancilio.

In addition, the encapsulator is primarily made of off-the-shelf components. This design facilitates maintenance, Sancilio explains.

Versatile drive offers quick setup


AF-650 GP drive (GE Consumer and Industrial)
GE Consumer and Industrial (Plainville, CT) recently introduced its "AF-650 GP" drive to control mixers and material-handling equipment. Paul Bunnell, product manager for GE, says the drive has both heavy- and light-duty ratings and "can do a constant-torque and variable-torque load in the same drive."

The unit's full display keypad facilitates setup. An "INFO" key built into the keypad is "analogous to having a manual online," Bunnell adds. The key provides parameter and setup information and status reports. In addition, the drive includes a Quick Menu of basic application parameters. The keypad also provides rotation-direction indication, custom user displays, trended data for speed, and torque.

The device's safe-stop functionality prevents it from starting unintentionally and eliminates the need for a separate unit to monitor the drive. This feature meets the EN 954-1 standard for Safety Category 3 installations.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here